Send to

Choose Destination
See comment in PubMed Commons below
Rheum Dis Clin North Am. 1997 Aug;23(3):619-55.

Classification and treatment of the juvenile idiopathic inflammatory myopathies.

Author information

Laboratory of Molecular and Developmental Immunology, Food and Drug Administration, Bethesda, Maryland, USA.


This article reviews the current status of the classification and treatment of the juvenile idiopathic inflammatory myopathies. The intent of classification is to define homogeneous groups that share similar clinical features, disease courses, and responses to therapy. The classification scheme proposed includes clinicopathologic subsets, serologic subjects based on the presence of myositis-specific and myositis-associated autoantibodies, and environmental triggers of myositis. Juvenile dermatomyositis is the most common and widely recognized of these disorders. The second part reviews the history of treatment of juvenile dermatomyositis and discusses agents to consider for patients with refractory disease, unacceptable steroid toxicity, or poor prognostic factors.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center